| Literature DB >> 31026178 |
Ali M Tabish1, Mohammed Arif2, Taejeong Song2, Zaher Elbeck1, Richard C Becker2, Ralph Knöll1,3, Sakthivel Sadayappan2.
Abstract
In this study, we investigated the role of DNA methylation [5-methylcytosine (5mC)] and 5-hydroxymethylcytosine (5hmC), epigenetic modifications that regulate gene activity, in dilated cardiomyopathy (DCM). A MYBPC3 mutant mouse model of DCM was compared with wild type and used to profile genomic 5mC and 5hmC changes by Chip-seq, and gene expression levels were analyzed by RNA-seq. Both 5mC-altered genes (957) and 5hmC-altered genes (2,022) were identified in DCM hearts. Diverse gene ontology and KEGG pathways were enriched for DCM phenotypes, such as inflammation, tissue fibrosis, cell death, cardiac remodeling, cardiomyocyte growth, and differentiation, as well as sarcomere structure. Hierarchical clustering of mapped genes affected by 5mC and 5hmC clearly differentiated DCM from wild-type phenotype. Based on these data, we propose that genomewide 5mC and 5hmC contents may play a major role in DCM pathogenesis. NEW & NOTEWORTHY Our data demonstrate that development of dilated cardiomyopathy in mice is associated with significant epigenetic changes, specifically in intronic regions, which, when combined with gene expression profiling data, highlight key signaling pathways involved in pathological cardiac remodeling and heart contractile dysfunction.Entities:
Keywords: DNA hydroxymethylation; DNA methylation; dilated cardiomyopathy; epigenetics
Mesh:
Substances:
Year: 2019 PMID: 31026178 PMCID: PMC6692731 DOI: 10.1152/ajpheart.00758.2018
Source DB: PubMed Journal: Am J Physiol Heart Circ Physiol ISSN: 0363-6135 Impact factor: 4.733